* Read the article on page 323.
* Take the test, recording your answers in the test answers section (Section B) of the CE enrollment form. Each question has only one correct answer.
* Complete registration information (Section A) and course evaluation (Section C).
* Mail completed test with registration fee to: Lippincott Williams & Wilkins, CE Group, 2710 Yorktowne Blvd., Brick, NJ 08723.
* Within 4-6 weeks after your CE enrollment form is received, you will be notified of your test results.
* If you pass, you will receive a certificate of earned contact hours and answer key. If you fail, you have the option of taking the test again at no additional cost.
* A passing score for this test is 12 correct answers.
* Need CE STAT? Visit www.nursingcenter.com for immediate results, other CE activities and your personalized CE planner tool.
* No Internet access? Call 1-800-787-8985, for other rush service options.
* Questions? Contact Lippincott Williams & Wilkins: 1-800-787-8985.
Registration Deadline: December 31, 2012
The authors have disclosed that they have no significant relationship with or financial interest in any commercial companies that pertain to this educational activity.
Lippincott Williams & Wilkins, publisher of Journal of Neuroscience Nursing, will award 1.9 contact hours for this continuing nursing education activity.
Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 1.9 contact hours. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia and Florida #FBN2454. Your certificate is valid in all states.
The ANCC's accreditation status of Lippincott Williams & Wilkins Department of Continuing Education refers only to its continuing nursing education activities and does not imply Commission on Accreditation approval or endorsement of any commercial product.
Payment and Discounts:
* The registration fee for AANN members is $9.00; for nonmembers, $18.00.
* AANN members-to get the discounted price (50% off) when taking the test online, log into the secure "Members Only" area of www.aann.org to get the discount code. Use the code when paying for CE courses on www.nursingcenter.com/CE/JNN.
* Send two or more tests in any nursing journal published by LWW together by mail, and deduct $0.95 from the price of each test.
* We offer special discounts for as few as six tests and institutional bulk discounts for multiple tests. Call 1-800-787-8985 for more information.
CE TEST QUESTIONS
GENERAL PURPOSE STATEMENT: To familiarize the registered professional nurse with a study analyzing the health status of long-term survivors of pediatric craniopharyngiomas.
LEARNING OBJECTIVES: After reading this article and taking this test, the nurse will be able to:
1. Describe the epidemiology and morbidity associated with craniopharyngiomas.
2. Discuss the results of this study and implications for nursing care.
1. Craniopharyngiomas account for what percentage of the total number of pediatric brain tumors?
2. The median age at diagnosis of a craniopharyngioma is
a. 2 years.
b. 4 years.
c. 6 years.
d. 8 years.
3. Histologically, craniopharyngiomas
a. grow aggressively.
b. are slowly invasive.
c. are benign.
d. are malignant.
4. Treatment-related morbidity results from damage to the hypothalamus and the
a. pineal gland.
b. pituitary gland.
5. Current treatment of craniopharyngiomas includes
a. aggressive surgical resection and radiation.
b. limited surgical resection and radiation.
c. aggressive surgical resection and chemotherapy.
d. limited surgical resection and chemotherapy.
6. The most common morbidities in the group of study patients included all except
a. neurocognitive problems.
b. neurological abnormalities.
c. emotional/psychological problems.
7. The most frequent endocrine dysfunction seen in the study group was
c. diabetes mellitus.
d. diabetes insipidus.
8. Communication disorders seen in the study group included written and verbal issues with
a. executive reasoning.
b. comprehension and expression.
c. short-term recall.
d. long-term recall.
9. According to Muller, which disorder followed 80%-95% of complete craniopharyngioma resection patients?
a. growth hormone deficiency
c. seizure disorders
d. diabetes insipidus
10. Which of the following was not identified by the authors as a potential barrier to compliance with hormone replacement therapy?
a. reliance on caregivers
b. adolescent rebellion
c. neurocognitive impairment
d. the cost of medications
11. A risk factor for development of obesity in craniopharyngioma survivors is
a. pineal gland involvement.
b. hypothalamic involvement.
12. The authors emphasize that, for craniopharyngioma survivors, it is a mistake to focus attention only on
a. neurological deficits.
b. endocrine deficits.
c. cognitive deficits.
d. behavioral deficits.
13. As many as two thirds of craniopharyngioma survivors experience
b. cerebrovascular disease.
c. visual deficits.
14. According to Merchant, studies show that craniopharyngioma survivors have
a. good long-term memory.
b. normal attentiveness.
c. low IQs.
d. slow reaction times.
15. The authors advocate that craniopharyngioma survivors may particularly benefit from
a. psychiatric treatment.
b. nutritional intervention.
c cognitive retraining.
d. digital technologies.
16. Research by Crom et al indicates that craniopharyngioma survivors have a great deal of anxiety about
a. their vulnerability.
b. hormonal therapy.
c. premature death.